An embodiment provides a method for detection of viral antigen for the COVID-19 virus, including: obtaining a body fluid from a patient; introducing the body fluid to at least one binding antibody, wherein the at least one binding antibody binds to an antigen of the SARS-CoV-2 spike (S) protein and comprises an indicator; forming a viral antigen—antibody complex; and determining the presence of the viral antigen—antibody complex. Other aspects are described and claimed.

Antibodies and antigen binding fragments that specifically bind to human metapneumovirus (hMPV) F protein and neutralize hMPV are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. The disclosed antibodies, antigen binding fragments, nucleic acids and vectors can be used, for example, to inhibit an hMPV infection or detect a hMPV infection.

Antibodies and antigen binding fragments that specifically bind to human metapneumovirus (hMPV) F protein and neutralize hMPV are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. The disclosed antibodies, antigen binding fragments, nucleic acids and vectors can be used, for example, to inhibit an hMPV infection or detect a hMPV infection.

Anti-RSV antibodies with neutralizing potency against RSV subtype A and RSV subtype B are provided, as well as nucleic acid sequences encoding such antibodies, methods for their identification, isolation, generation, and methods for their preparation and use are provided.

The present disclosure is directed to antibodies binding to and neutralizing Zika vims and methods for use thereof.

The present disclosure is directed to antibodies binding to and neutralizing Zika vims and methods for use thereof.

The present disclosure is directed to antibodies binding to and neutralizing dengue virus and methods for use thereof.

The present invention relates to antibodies or antigen-binding fragments that are useful for treating influenza B viruses. The present invention also relates to various pharmaceutical compositions and methods of treating influenza using the antibodies or antigen-binding fragments.

Antibodies and antigen-binding fragments thereof specific to the YFV E protein and with neutralizing potency against YFV are provided. These antibodies and antigen-binding fragments are useful in treating YFV.

Antibodies and antigen-binding fragments thereof specific to the YFV E protein and with neutralizing potency against YFV are provided. These antibodies and antigen-binding fragments are useful in treating YFV.